Article

Patterns of MRI atrophy in tau positive and ubiquitin positive frontotemporal lobar degeneration.

Memory and Aging Center, and Department of Neurology, University of California, San Francisco, San Francisco, California 94117, USA.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 4.87). 01/2008; 78(12):1375-8. DOI: 10.1136/jnnp.2006.114231
Source: PubMed

ABSTRACT We applied optimised voxel based morphometry (VBM) to brain MRIs from autopsy proven cases of tau positive frontotemporal lobar degeneration (FTLD-T, n = 6), ubiquitin and TDP-43 positive/tau negative FTLD (FTLD-U, n = 8) and cognitively normal controls (n = 61). The analysis revealed that FTLD-T and FTLD-U both show atrophy in the frontal cortex and striatum, but striatal atrophy is more severe in FTLD-T. Manual region of interest tracing of caudate and putamen volumes confirmed the VBM findings. These anatomical differences may help distinguish between FTLD spectrum pathological subtypes in vivo.

0 Bookmarks
 · 
75 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease characterized by brain atrophy of the frontal and anterior temporal lobes. The associated frontotemporal dementia syndromes are clinically heterogeneous and the pattern of affected cortical regions varies between subtypes. The TMEM106B rs1990622 polymorphism is associated with FTLD, but little is known about how it affects the brain. Methods We investigated the rs1990622 polymorphism in relation to regional brain volumes to identify potential structures through which TMEM106B confers risk for FTLD. In 4413 non-demented and stroke-free participants from the population-based Rotterdam Study, 150 cortical brain structures and 6 commissural regions were segmented from magnetic resonance imaging (MRI). Results We found a distinct pattern of association between rs1990622 and grey matter volume of left-sided temporal brain regions important for language processing, including the superior temporal gyrus (β = -88.8 μL per risk allele, p = 7.64 x 10-5), which contains Wernicke’s area. The risk allele was also associated with a smaller anterior commissure cross-sectional area (β = -.167 mm2 per risk allele, p = 4.90 x 10-5) and posterior part of the corpus callosum (β = -15.3 μL per risk allele, p = 1.23 X 10-5), both of which contain temporal lobe commissural tracts. Conclusions The asymmetric, predominantly left-sided involvement suggests an effect of TMEM106B on functions lateralized to the dominant hemisphere, such as language. These results show that, in non-demented persons, TMEM106B influences the volume of temporal brain regions which are important for language processing.
    Biological psychiatry 01/2014; · 8.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the search for therapeutic modifiers, frontotemporal dementia (FTD) has traditionally been overshadowed by other conditions such as Alzheimer's disease (AD). A clinically and pathologically diverse condition, FTD has been galvanized by a number of recent discoveries such as novel genetic variants in familial and sporadic forms of disease and the identification of TAR DNA binding protein of 43 kDa (TDP-43) as the defining constituent of inclusions in more than half of cases. In combination with an ever-expanding knowledge of the function and dysfunction of tau—a protein which is pathologically aggregated in the majority of the remaining cases—there exists a greater understanding of FTD than ever before. These advances may indicate potential approaches for the development of hypothetical therapeutics, but FTD remains highly complex and the roles of tau and TDP-43 in neurodegeneration are still wholly unclear. Here the challenges facing potential therapeutic strategies are discussed, which include sufficiently accurate disease diagnosis and sophisticated technology to deliver effective therapies.
    Frontiers in Aging Neuroscience 08/2014; · 5.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study of olfaction in neurodegeneration has primarily focused on Alzheimer's disease. Research of olfaction in frontotemporal dementia (FTD) has generally not been empirically studied. The current study compared olfaction in FTD to major depressive disorder (MDD) using the Alberta Smell Test (AST). Independent-samples t test results suggested olfaction in FTD was impaired when compared with participants diagnosed with MDD. The AST Total score (out of 20 trials) significantly predicted the diagnostic group and accounted for 40% of the variance in diagnostic group status with an odds ratio of 20.08. Results suggested that a cutoff of ≤2/20 differentiated FTD from MDD with 94% accuracy (91% sensitivity, 97% specificity) and a cutoff of ≤1/20 differentiated the groups with a 95.5% hit rate (91% sensitivity, 100% specificity). Results confirmed olfactory identification deficits in FTD and suggested that the AST is an effective tool for the demarcation of FTD from MDD. This is especially important due to the potential for significant overlap in the behavioral/emotional phenotype and cognitive deficits between the two disorders when presented with early stages of FTD.
    Applied neuropsychology. Adult. 07/2014; 21(3):176-182.

Full-text

Download
0 Downloads
Available from